Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Health Syst Pharm ; 67(14): 1178-80, 2010 Jul 15.
Article in English | MEDLINE | ID: mdl-20592323

ABSTRACT

PURPOSE: A case of topiramate-induced myoclonus and acute psychosis in a patient taking the recommended dosage of topiramate for migraine prophylaxis is reported. SUMMARY: A 29-year-old Caucasian, wheelchair-bound woman with diplegic cerebral palsy and a history of migraines was admitted to the hospital after developing paranoid thoughts and episodes of myoclonus two weeks after an increase in her topiramate dosage (25 mg twice daily to 50 mg twice daily). Her physical examination upon admission was unremarkable, with the exception of a temperature of 38.2 degrees C. Diagnostic laboratory test values, including those of the cerebrospinal fluid, were within normal limits. During neurologic examination, arm jerking, lip smacking, and finger movements occurred spontaneously and unprovoked, and severe bilateral leg myoclonus with plantar stimulation was observed. The results of an ultrasound of her lower extremities and a computed tomography scan of the brain with and without contrast revealed no abnormalities. An electroencephalogram was taken and showed nothing unusual. After nonpharmacologic etiologies were ruled out, her topiramate dosage was decreased and discontinued over four days. Her mental status and myoclonus drastically improved. She was stable and discharged within 24 hours of topiramate discontinuation. Follow-up at six months revealed that her myoclonus had completely resolved. While she has experienced additional psychotic episodes, these were mild and appear to be related to her depression. Myoclonus has not returned. CONCLUSION: A patient with cerebral palsy experienced myoclonus and acute psychosis after receiving a standard dosage of topiramate for migraine prophylaxis.


Subject(s)
Fructose/analogs & derivatives , Myoclonus/chemically induced , Psychoses, Substance-Induced/etiology , Adult , Anticonvulsants/administration & dosage , Anticonvulsants/adverse effects , Anticonvulsants/therapeutic use , Cerebral Palsy/complications , Dose-Response Relationship, Drug , Female , Follow-Up Studies , Fructose/administration & dosage , Fructose/adverse effects , Fructose/therapeutic use , Humans , Migraine Disorders/prevention & control , Topiramate
2.
Environ Toxicol Chem ; 22(1): 175-81, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12503762

ABSTRACT

Deoxyribonucleic acid (DNA) microarrays provide a means to assess genome-wide expression patterns after exposure of an organism to different xenobiotics. Potential uses for this technology include identification of unknown toxicants, assessment of toxicity of new compounds, and characterization of the cellular mechanisms of toxicant action. Here we describe another use of DNA microarrays in toxicant-specific gene discovery. Combining results from two DNA microarray experiments, we have identified genes from the model plant Arabidopsis thaliana that are induced in response to one but not other heavy metals. The promoters of these genes should be useful in developing metal-specific transgenic biomonitors. To test this idea, we have fused the promoter of one of the newly identified Ni-inducible genes (AHB1) to the beta-glucuronidase (GUS) reporter gene. Arabidopsis plants containing the AHBI::GUS transgene show reporter gene activity when they are grown on media containing Ni but not when grown on media containing Cd, Cu, Zn, or without added metals. Thus, this approach has resulted in the creation of a transgenic strain of Arabidopsis that can report on the presence and concentration of Ni in plant growth media. Such transgenic models can serve as cheap and efficient biomonitors of bioavailable heavy metal contamination in soils and sediments.


Subject(s)
Brassicaceae/genetics , Metals, Heavy/toxicity , Oligonucleotide Array Sequence Analysis , Plants, Genetically Modified , Biological Availability , Biomarkers/analysis , Environmental Monitoring/methods , Metals, Heavy/pharmacokinetics
SELECTION OF CITATIONS
SEARCH DETAIL
...